close
close
Posted in

Traverse Biotech Receives Phase I SBIR Grant from National Institute of Allergy and Infectious Diseases to Develop an Innate Immune Stimulator

NEW YORK, May 1, 2024 /PRNewswire/ — Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. This grant will support the development of our oral innate stimulation modality for immunotherapy, with a focus on evaluating monocytic cellular activation using pathogen-associated molecular patterns (PAMPs) motifs.

Brandy Huiserco-founder and CEO of Traverse Biotech, said: “We are grateful for the support from NIAID. We believe our product candidate has broad applicability to various immunological pathologies in which myeloid-derived cells are dysfunctional and ultimately ineffective in resolving disease. “

This work will be carried out in collaboration with Dr. Sara Lustigman, chief of the Division of Molecular Parasitology at the Lindsley F. Kimball Research Institute of New York Blood Center Enterprises. The extensive academic research of Dr. Lustigman in immunology and infectious diseases will enable the evaluation of Traverse’s innate immune stimulator mechanism in validated preclinical pathogenic models.

About Traverse Biotech, Inc. is a privately held American biotechnology company developing innovative immunotherapy products. Traverse Biotech focuses on the late-stage preclinical and early clinical development of product candidates derived from risk-free technology platforms. For each product in the pipeline, Traverse grants global commercialization rights to select international biopharmaceutical companies that are divesting promising product candidates due to strategic portfolio rationalization. Through an original partnership model, Traverse Biotech accelerates the therapeutic development of each agent through clinical proof-of-concept. The flexible and streamlined operational structure enables rapid clinical assessment and cost reduction across all aspects of product development, reaching patients faster.

SOURCE Traverse Biotech